+++
title = "About"
slug = "about"
bgImage = "/img/aboutBg.jpg"
+++


Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases. Our lead therapeutic candidate, ATI-2173, is a first-in-class Active Site Polymerase Inhibitor Nucleotide (ASPIN) that is in development as the backbone of an oral, once-daily potential curative therapy for HBV.

To-date, ATI-2173 has completed Phase 1 studies in both healthy volunteers and HBV-infected individuals. Data from the Phase 1b study in HVB-infected patients are expected to be reported in 2021.A Phase 2a study (both mono- and combination therapy) is expected to be initiated later in 2021.